Treat-to-Target of Endoscopic Remission in Patients with IBD in Symptomatic Remission

Brief description of study

The purpose of this research study is to collect and analyze data in participants with inflammatory bowel disease (IBD) who are currently receiving IBD medication(s) that targets their immune system (targeted immunomodulator [TIM]) in routine clinical care and to determine if switching to an alternative IBD medication will improve their disease outcome without increasing the burden of their treatment.

Clinical Study Identifier: s22-01269
Principal Investigator: David P Hudesman.

If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.